Another preclinical study showed that whole-tumor vaccines producing granulocyte macrophage colony-stimulating factor (GM-CSF) greatly enhanced anti-CTLA-4 blockade efficacy against pancreatic and prostate cancers. Here, CSF2 is linked to prostate carcinoma.